Mirum Pharmaceuticals Q4 2023 GAAP EPS $(0.66) Misses $(0.24) Estimate, Sales $69.55M Beat $67.76M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals (NASDAQ:MIRM) reported Q4 2023 earnings with a GAAP EPS of $(0.66), missing the $(0.24) estimate by 175%. However, their sales of $69.55M exceeded the $67.76M estimate by 2.64%, marking a 149.24% increase from the same period last year.
February 28, 2024 | 9:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mirum Pharmaceuticals reported a significant miss on EPS but exceeded sales estimates in Q4 2023, with a notable year-over-year sales growth.
The significant miss on EPS could negatively impact investor sentiment and stock price in the short term. However, the better-than-expected sales figures and substantial year-over-year growth might offset some of the negative impact. Given the mixed results, the short-term impact on MIRM's stock price is uncertain, hence a neutral score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100